25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital- markets experience as Atossa prepares for commercial operations with (Z)-endoxifen , /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior financ ...